A Prospective, Single-arm, Exploratory Study of Trifluridine/Tipiracil (TAS-102) Combined With Apatinib as Third-line Therapy for Advanced Gastric Cancer

NCT07371871 · clinicaltrials.gov ↗

NA

Phase

NOT_YET_RECRUITING

Status

30

Enrollment

OTHER

Sponsor class

Conditions

Advanced Gastric Cancer

Interventions

DRUG: Trifluridine/Tipiracil (TAS-102) combined with Apatinib

Sponsor

Anhui Provincial Cancer Hospital